AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing

Read More

Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™)

Read Paper

AmberGen awarded $2 million, 2-year Phase IIb SBIR grant from NIH-NIAID to further develop its PC-PURE™-assisted, multiplex, in vitro AllerBead™ assay which uses finger-stick blood for the highly multiplex quantification of allergen-specific IgE

AmberGen acquires a new state-of-the-art Bruker rapifleX™ MALDI mass spectrometer for ultra-fast and high resolution mass spectrometry imaging of its Bead-AMS™ proteomic bead-arrays

Dr. Gargey Yagnik joins AmberGen as Program Coordinator for Mass Spectrometry. In his previous position as a postdoctoral researcher at Sanofi Genzyme he developed new methods for MALDI-MSI tissue imaging. He received his Ph.D. from Iowa State University in analytical chemistry.

AmberGen awarded two US Patents (9,513,285 and 9,523,680) providing broad coverage for its Bead-AMS™ technologies

Learn More

AmberGen Founder and Chairman of the Board, Dr. Ken Rothschild, was elected as a Fellow of the National Academy of Inventors (NAI). The election as an NAI Fellow honors contributions from inventors who have made a tangible impact on quality of life, economic development and welfare of society.

AmberGen pioneers new Bead Array Mass Spectrometry Technology (Bead-AMS™) and is awarded 3 U.S. patents providing broad coverage

AmberGen awarded 3-year Phase II SBIR grant from NIH-NIGMS to develop Bead-AMS™ for screening on- and off-target drug binding on a proteome-wide scale

AmberGen awarded Phase I SBIR grant from NIH-NCI IMAT program to develop PC-PURE™ for the detection of serological ovarian cancer biomarkers